Amira Pharmaceuticals

Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461

Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM211, a Novel Product Candidate for the Treatment of Respiratory Diseases

Amira Pharmaceuticals to Present Preclinical Data from LPA1 Receptor Antagonist Program at FASEB Summer Research Conference

Amira Initiates Phase I Clinical Trial of Novel DP2 Antagonist

SAN DIEGO - Amira Pharmaceuticals, Inc.

MORE..

SAN DIEGO - - Results Demonstrate Positive Proof of Mechanism Amira Pharmaceuticals, Inc.

MORE..

SAN DIEGO - Amira Pharmaceuticals, Inc.

MORE..

Older News

SAN DIEGO - Trial Will Evaluate Safety, Proof of Mechanism of a Potential Oral Antagonist for the Treatment of Asthma and COPD Amira Pharmaceuticals, Inc., announced today the initiation of a Phase I clinical study of AM211, its internally discovered oral drug candidate for the treatment and control of inflammatory and allergic diseases linked to the arachidonic acid pathway.

MORE..